Evidence map›Paper›PMID 41709034›Full record

ArticleAAPS PharmSciTech2026

Harnessing Novel Tetra-Synergistic Bilosomes for Effective Otomycosis Management: Integrated In-Vitro, Microbiological and In-vivo Studies.

Abdurrahman M Fahmy, Osama Saher, Heba Attia, Michael M Farag, Sadek Ahmed

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Innovative hyaluronic acid-decorated quatsomes for enhanced renal targeting: design, optimization andJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Abdurrahman M FahmyDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, P.O. Box 11562, Cairo, Egypt.ORCID http://orcid.org/0000-0003-3003-6541
Osama SaherDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, P.O. Box 11562, Cairo, Egypt. osama.saher@ki.se.ORCID http://orcid.org/0000-0003-3286-5706
Heba AttiaDepartment of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0000-0001-9880-1751
Michael M FaragDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, P.O. Box 11562, Cairo, Egypt.ORCID http://orcid.org/0000-0002-9718-3741
Sadek AhmedDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, P.O. Box 11562, Cairo, Egypt.ORCID http://orcid.org/0000-0002-0190-9502

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study introduces and statistically optimizes novel Tetra-Synergistic Bilosomes (TSB), an advanced nano-platform for topical delivery of voriconazole (VOR) in otomycosis therapy. The term "Tetra-Synergistic" reflects the incorporation of four complementary components: Cremophor® EL, sodium deoxycholate, Brij® 58, and Brij® S2, working in synergy to enhance therapeutic efficacy. TSB was fabricated using the thin-film hydration method and optimized through a 2

Indexed as

Antifungal AgentsCetomacrogolDeoxycholic AcidGlycerolNanoparticle Drug Delivery SystemOtomycosisVoriconazoleAdministration, TopicalAnimalsAspergillus nigerDrug SynergismMaleMicrobial Sensitivity TestsRabbitsSkinAntifungal AgentsCetomacrogolcremophor ELDeoxycholic AcidGlycerolNanoparticle Drug Delivery SystemVoriconazoleD-optimal designin vivo permeationminimum fungicidal concentrationtetra-synergistic bilosomestime to kill assayvoriconazole

Identifiers

PMID41709034

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.